8:08AM ISIS Pharm reports 'encouraging' interim Phase 1 data on ISIS-STAT3Rx in patients with cancer (ISIS) 8.90 : Co announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston. Interim results of the initial dose escalation study in patients with cancer showed that ISIS-STAT3Rx treatment resulted in clear responses in patients with advanced cancer who were refractory to prior chemotherapy treatment, with an acceptable safety profile. Based on these results, Isis has initiated a Phase 2 study in focused patient populations with advanced cancer.
Market Data 
Markets 
AI
